Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-09-01
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514274, 544310, 544311, 544312, A61K 31505, C07D23902
Patent
active
058011820
ABSTRACT:
Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:
REFERENCES:
patent: 3245994 (1966-04-01), Klingler et al.
patent: 3422107 (1969-01-01), Mohler et al.
patent: 3737433 (1973-06-01), Mohler et al.
patent: 4061753 (1977-12-01), Bodor et al.
patent: 4144340 (1979-03-01), Offermans et al.
patent: 4275064 (1981-06-01), Bodor et al.
patent: 4279992 (1981-07-01), Borguslaski et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4374837 (1983-02-01), Favier et al.
patent: 4515795 (1985-05-01), Hinze et al.
patent: 4542137 (1985-09-01), Klessing et al.
patent: 4558051 (1985-12-01), Sunshine et al.
patent: 4565817 (1986-01-01), Korbonits et al.
patent: 4576947 (1986-03-01), Hinze et al.
patent: 4618612 (1986-10-01), Baglioni
patent: 4636507 (1987-01-01), Kreutzer et al.
patent: 4784994 (1988-11-01), Romer et al.
patent: 4833146 (1989-05-01), Gebert et al.
patent: 4845081 (1989-07-01), Sloan
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5039666 (1991-08-01), Novick, Jr.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5118500 (1992-06-01), Hael et al.
patent: 5126340 (1992-06-01), Tseng et al.
patent: 5196439 (1993-03-01), Sugimoto et al.
patent: 5247086 (1993-09-01), Cain et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: B13737433 (1987-03-01), Mohler et al.
Bianco et al., Blood, 76: Supplement 1 (522), p. 133a, "Pentoxifylline (PTX) and GM-CSF Decrease Tumor Necrosis Factor-Alpha (TNF-.alpha.) Levels in Patients Undergoing Allogeneic Bone Marrow Transplantation (BMT)", 1990.
Bianco et al., Blood, 78:5, pp. 1205-1211, "Phase I-II Trial of Pentoxifylline for the Prevention of Transplant-Related Toxicities Following Bone Marrow Transplantation", Sep. 1991.
Bursten et al., The Journal of Biological Chemistry, vol. 266, No. 31, pp. 20732-20743, "Interleukin-1 Rapidly Stimulates Lysophosphatidate Acyltransferase and Phosphatidate activities in Human Mesangial Cells", Nov. 1991.
Davis et al., Applied Environment Microbial., 48:2, pp. 327-331, "Microbial Models of Mammalian Metabolism: Microbial Reduction and Oxidation of Pentoxifylline", Aug. 1984.
Ridder., Chemical Abstracts, vol. 60, col. 15892, "Derivatives of dialkylxanthines", Jan. 1964.
Constant et al., Synthetic Models Related to DNA Intercalating Molecules: Preparation of 9-Aminoacridines Linked to the Nucleotide Bases Adenine, Guanine, and Thymine, J;. Heterocyclic Chem., vol. 22, pp. 1035-1040, Jul. 1985.
Singer et al., "Effect of Methylxanthine Derivatives on T Cell Activation", Bone Marrow Transplantation vol. 10, No. 19, pp. 19-25, 1992.
Klein J. Peter
Kumar Anil M.
Ridgers Lance H.
Underiner Gail E.
Cell Therapeutics Inc.
Coleman Brenda
Shah Mukund J.
LandOfFree
Amine substituted compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amine substituted compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine substituted compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270589